Skip to contents

Data frame containing the results of 50 trials of 8 thrombolytic drugs (streptokinase, SK; alteplase, t-PA; accelerated alteplase, Acc t-PA; streptokinase plus alteplase, SK+tPA; reteplase, r-PA; tenocteplase, TNK; urokinase, UK; anistreptilase, ASPAC) plus per-cutaneous transluminal coronary angioplasty (PTCA) (Boland et al. 2003; Lu and Ades 2006; Dias et al. 2011) . The number of deaths in 30 or 35 days following acute myocardial infarction are recorded.

Usage

thrombolytics

Format

A data frame with 102 rows and 5 variables:

studyn

numeric study ID

trtn

numeric treatment code

trtc

treatment name

r

total number of events

n

total number of individuals

References

Boland A, Dundar Y, Bagust A, Haycox A, Hill R, Mota RM, Walley T, Dickson R (2003). “Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation.” Health Technology Assessment, 7(15). doi:10.3310/hta7150 .

Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE (2011). “NICE DSU Technical Support Document 4: Inconsistency in networks of evidence based on randomised controlled trials.” National Institute for Health and Care Excellence. https://www.sheffield.ac.uk/nice-dsu.

Lu GB, Ades AE (2006). “Assessing evidence inconsistency in mixed treatment comparisons.” Journal of the American Statistical Association, 101(474), 447–459. doi:10.1198/016214505000001302 .